SCHEMBL4881971

SCHEMBL4881971

COc1c(C)cccc1N=C=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.57
ALDH1A1 P00352 4/20 0.43
HPGD P15428 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
TRPA1 O75762 1/20 0.42
GABRA1 P14867 1/20 0.36
GABRB2 P47870 1/20 0.36
KDM4E B2RXH2 3/20 0.32
HSD17B10 Q99714 2/20 0.32
SMN1; SMN2 Q16637 3/20 0.31
MAPK1 P28482 2/20 0.31
PTPN1 P18031 1/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
APLNR P35414 1/20 0.31
SCN4A P35499 3/20 0.31
TSHR P16473 2/20 0.31
LMNA P02545 2/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9102591 0.88 CYP3A4 (0.59) CYP3A4ALDH1A1HPGDTDP1TRPA1
SCHEMBL1332133 0.81 CYP3A4 (0.57) CYP3A4ALDH1A1HPGDTDP1KDM4E
SCHEMBL30438740 0.81 CYP3A4 (0.57) CYP3A4ALDH1A1HPGDTDP1KDM4E
SCHEMBL16707539 0.81 CYP3A4 (0.52) CYP3A4ALDH1A1HPGDTDP1TRPA1
SCHEMBL3548255 0.80 CYP3A4 (0.50) CYP3A4ALDH1A1HPGDTDP1TRPA1
SCHEMBL7534773 0.77 CYP3A4 (0.56) CYP3A4ALDH1A1HPGDTDP1TRPA1
SCHEMBL93192 0.76 CYP3A4 (0.79) CYP3A4ALDH1A1HPGDTDP1TRPA1
SCHEMBL29440559 0.76 CYP3A4 (0.79) CYP3A4ALDH1A1HPGDTDP1TRPA1
SCHEMBL1513786 0.76 CYP3A4 (0.46) CYP3A4ALDH1A1HPGDTDP1TRPA1
SCHEMBL93287 0.76 CYP3A4 (0.64) CYP3A4ALDH1A1HPGDTDP1TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105339359-B Terazololine-one compound and application thereof 住友化学株式会社 2018-02-16 CN disclosed
CN-107001244-A The manufacture method of isocyanate compound 住友化学株式会社 2017-08-01 CN disclosed
CN-107001244-A The manufacture method of isocyanate compound 住友化学株式会社 2017-08-01 CN disclosed
US-8754107-B2 Aminopyrrolidines as chemokine receptor antagonists ABBVIE INC. (US) 2014-06-17 US disclosed
US-20080176883-A1 Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone ABBVIE INC. 2008-07-24 US disclosed
US-4437919-A POLYISOCYANATE, ENDCAPPED POLYETHERSILOXANE FIBER INDUSTRIES, INC. (US) 1984-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176883-A1 Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone MIF, CCL5, CCR2 CYP3A4 916/4885ALDH1A1 433/4885HPGD 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.